The study examines a cholesterol‑lowering medication that combines ezetimibe and atorvastatin. Two versions are compared: a standard tablet and a film‑coated tablet. This medication is normally taken by mouth to help lower high cholesterol, a condition that can increase the risk of heart problems.

The purpose of the study is to evaluate the relative bioavailability of the test formulation compared with the commercial reference and to demonstrate their bioequivalence according to health‑authority criteria. Healthy adults will receive a single dose of one formulation after an overnight fast, then, after a short break, will receive the other formulation. Blood samples will be taken over several hours to measure how much of the drug reaches the bloodstream, looking at total exposure (AUC), the highest concentration reached (Cmax) and the time it takes to reach that peak (Tmax).

Volunteers will be monitored for any side effects while staying in a comfortable setting, and the study will be completed in a short period of time with only a few clinic visits. No disease is being treated in the participants; the goal is simply to confirm that the two tablet types behave the same way in the body.